Teriparatide treatment in adult hypophosphatasia in a patient exposed to bisphosphonate: A case report

Clinical Cases in Mineral and Bone Metabolism

Volumn 6, Issue 3, 2009, Pages 266-269

  Doshi, Krupa B ^a   Hamrahian, Amir H ^a   Licata, Angelo A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alkaline phosphatase: Pyridoxal phosphate; Osteomalacia

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; AZELASTINE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYANOCOBALAMIN; DESLORATADINE; IRON; LORAZEPAM; PARATHYROID HORMONE[1-34]; PRIMIDONE; PYRIDOXAL 5 PHOSPHATE; RISEDRONIC ACID; VITAMIN D;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE PAIN; CASE REPORT; CAUCASIAN; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS LINKING; DIZZINESS; DRUG EXPOSURE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR FRACTURE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HAY FEVER; HUMAN; HYPOPHOSPHATASIA; INTRAMEDULLARY NAIL; MOBILIZATION; OFF LABEL DRUG USE; OSSIFICATION; OUTCOME ASSESSMENT; SEIZURE; STATISTICAL SIGNIFICANCE; STRESS FRACTURE; TREATMENT DURATION; TREATMENT OUTCOME; URINE LEVEL; WALKING AID; WEIGHT BEARING; WHEELCHAIR;

EID: 76749102085     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev. 1994;15:439-461.
2. Whyte MP, Mumm S, Deal C. Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab. 2007;92:1203-1208.
3. Camacho PM, Painter S, Kadanoff R. Treatment of adult hypophosphatasia with teriparatide. Endocr Pract. 2008;14:204-208.
4. Obermayer-Pietsch BM, Marin F, McCloskey EV et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23:1591-1600.
5. Miller PD, Delmas PD, Lindsay R et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93:3785-3793.
6. Neer RM, Arnaud CD, Zanchetta JR. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344: 1434-1441.
7. Licata AA. Osteoporosis, teriparatide, and dosing of calcium and vitamin D. N Engl J Med. 2005;352:1930-1931.
8. Vieth R, Cole DEC, Krege JH. et al. Teriparatide. Osteoporosis, Calcium, and Vitamin D. N Engl J Med. 2005;353:634-635.
9. Coe JD, Murphy WA, Whyte MP. Management of femoral fractures and pseudofractures in adult hypophosphatasia. J Bone Joint Surg Am.1986:68:981-990.
10. Alkhiary YM, Gerstenfeld LC, Krall E et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005;87:731-741.
11. Millan JL, Narisawa S, Lemire I. et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2001;23:777-787